Goldman Sachs maintains neutral on Ionis Pharmaceuticals
Goldman Sachs maintains a neutral rating on Ionis Pharmaceuticals.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.